Chiesi, Gossamer to advance seralutinib for PAH, other disorders
Chiesi Group has reached an agreement with Gossamer Bio to develop and market seralutinib for certain types of pulmonary hypertension (PH). The agreement seeks to support the therapy’s ongoing testing in pulmonary arterial hypertension (PAH) and to accelerate its development for pulmonary hypertension associated with…